naturemary expands pain and women’s health R&D from PMDD origins

naturemary is expanding its Canadian commercialization and research platform as founder Sonia Mary Kalra turns a personal PMDD struggle into a broader push for pain and women’s health solutions. The Calgary company is investing in manufacturing, testing and next-generation therapeutics while growing pharmacy and retail distribution across Canada.

Why it matters: - naturemary is positioning pain relief and women’s health as a larger innovation category, not just a consumer product line. - The company’s focus on PMDD, hormonal symptoms, chronic pain and inflammation reflects an unmet-need area in women’s health. - The expansion could widen access to science-driven, naturally derived therapeutic options for women who say their symptoms are often under-recognized.

What happened: - Sonia Mary Kalra founded naturemary after searching for ways to manage her own Premenstrual Dysphoric Disorder symptoms. - Kalra is a biologist and neuroscience researcher with a background in neural plasticity. - naturemary started with small-batch, hand-labeled formulations made for personal use and shared with friends and early users. - The company is based in Calgary, Alberta, Canada, and is now growing through Canadian pharmacy and retail channels. - naturemary is also expanding internationally, along with its research and development pipeline.

The details: - The company is building out a new naturemary Manufacturing & Innovation Hub in Calgary. - naturemary is increasing investment in research, formulation, testing and manufacturing capabilities. - The company is exploring next-generation therapeutic formulations and technologies for pain and other unmet needs. - naturemary’s longer-term work includes areas tied to women’s health, biology, neuroscience, formulation science and naturally derived compounds. - Founder and CEO Sonia Mary Kalra said her PMDD experience led her to ask broader questions about women’s health, research and choice. - Kalra said the company’s mission now extends beyond PMDD into pain, inflammation, neurological pathways and how naturally derived compounds interact with the human body.

Between the lines: - The company’s origin story gives naturemary a built-in women’s health narrative that is personal, not generic. - That framing may help differentiate naturemary in a crowded wellness market by tying product development to research and therapeutic innovation. - The shift from small-batch products to national distribution suggests the company is trying to move from early consumer demand to a broader health platform. - Kalra’s comments point to a strategy built around credibility in women’s health, an area that still receives uneven research attention.

What's next: - naturemary plans to keep expanding its Canadian commercialization platform. - The company is expected to continue investing in R&D, formulation and manufacturing as it develops new therapeutic approaches. - Future work will likely center on pain relief and women’s health solutions that address hormonal and inflammatory symptoms. - Kalra said the company wants to advance the science and create more choices for women.

The bottom line: - naturemary is evolving from a personal PMDD solution into a Canadian health company aiming to build next-generation treatments for pain and women’s health.